Developer docs
API playgroundTry for free, no card

Search company profiles

OrphanPacific

Full company profile

uuid002fg37

Namestring
OrphanPacific
Legal namestring
OrphanPacific, Inc.
Company typeenum
Private
Founded yearint
2012
Descriptiontext

OrphanPacific, Inc. (株式会社オーファンパシフィック) is a Tokyo-based specialty pharmaceutical company founded on May 1, 2012 as a joint venture between CMIC Holdings Co., Ltd. (51%) and Medipal Holdings Corporation (49%) with paid-in capital of 100 million yen. The company develops and commercializes orphan drugs for rare diseases in Japan, addressing an estimated gap where approximately half of orphan drugs approved in the US and EU remain unapproved in Japan. Its portfolio spans approximately ten products including Buphenyl and Ravicti for urea cycle disorders, Normosang for acute porphyria, Dantrium for malignant hyperthermia and neuroleptic malignant syndrome, Diazoxide for hyperinsulinemic hypoglycemia, Rasilez for hypertension, Rynspad for severe α1-antitrypsin deficiency, Rabipur for rabies prevention, and the recently approved Joenja (leniolisib) for activated PI3K delta syndrome (APDS) and Ravicti oral liquid.

The company operates under its proprietary "Innovative Pharma Model" (IPM), which leverages CMIC Holdings' pharmaceutical development and manufacturing infrastructure alongside Medipal Holdings' pharmaceutical distribution network—one of Japan's largest—to efficiently bring globally-developed orphan drugs to Japanese patients. OrphanPacific generates revenue through pharmaceutical product sales (one-time licensing model) to healthcare institutions via a direct sales force of medical representatives (MRs), targeting physicians and pharmacists who treat rare disease patients. The company engages in licensing partnerships with international developers such as Pharming Group (Joenja) and Immedica Pharma (Ravicti) to expand its portfolio, distributes products through Medipal's wholesaler network, and supports healthcare professional and patient community engagement via medical conferences, disease awareness websites, and the OPOS online information service. Headcount stands at 51–100 employees, and the company recently relocated its Tokyo head office in July 2025.

Short descriptiontext

OrphanPacific is a Tokyo-based specialty pharmaceutical company that develops and commercializes orphan drugs for rare diseases in Japan, operating as a joint venture between CMIC Holdings and Medipal Holdings with a portfolio of approximately ten specialty products.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersTokyo, Japan
HQ citystring
Tokyo
HQ countrystring
Japan
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
orphan drug development, rare disease therapeutics, specialty pharmaceuticals, pharmaceutical distribution, rare disease commercialization
Industry4 codes
PRIMARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAL
Rare Gastroenterology & Hepatology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAG
Pulmonary Hypertension & Rare Pulmonary Disease Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAJ
Rare Endocrine & Growth Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Orphan Pharmaceuticals (Rare Disease Drugs)
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical product sales
TypeOne Time License
Description

OrphanPacific develops and commercializes orphan drugs (稀少疾病用医薬品) for the Japanese market, generating revenue through sales of specialty pharmaceuticals targeting rare diseases. Products include treatments for urea cycle disorders (Ravicti®, Buphenyl®), acute porphyria (Normosang®), malignant hyperthermia/malignant syndrome (Dantrium®), hyperinsulinemic hypoglycemia (Diazoxide), hypertension (Rasilez®), and alpha-1 antitrypsin deficiency (Rinsoeed™).

orphanpacific.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

OrphanPacific develops, in-licenses, and commercializes orphan drugs (rare disease pharmaceuticals) for the Japanese market under its proprietary Innovative Pharma Model (IPM). The company handles the full life cycle from obtaining marketing/manufacturing-sales approval to nationwide sales through medical representatives and pharmaceutical wholesalers, addressing rare conditions such as urea cycle disorders, acute porphyria, malignant hyperthermia, alpha-1 antitrypsin deficiency, hyperinsulinemic hypoglycemia, hypertension, and activated PI3K delta syndrome (APDS).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Over 10 years of continuous orphan drug supply in Japan
Product overview1 text field

OrphanPacific operates as a pharmaceutical company specializing in orphan drugs (稀少疾病用医薬品) for rare diseases in Japan. Their portfolio is not a unified software platform but rather a collection of prescription pharmaceutical products commercialized through licensing agreements. The company focuses on urea cycle disorders, acute porphyria, malignant hyperthermia, α1-antitrypsin deficiency, and other rare conditions. Products include Ravicti and Buphenyl for urea cycle disorders, Normosang for acute porphyria, Dantrium for malignant hyperthermia, and various other specialty pharmaceuticals.

Product and service12 records
1Ravicti (ラヴィクティ, glycerol phenylbutyrate)
CategoryPharmaceutical (Orphan Drug)
Description

Oral liquid formulation (1.1 g/mL) for the chronic management of urea cycle disorders (UCDs) — a group of rare inherited metabolic conditions in which the body cannot properly remove ammonia from the blood. Commercialized in Japan by OrphanPacific under license from Immedica Pharma AB; intended for patients with UCDs.

2Buphenyl (ブフェニル, sodium phenylbutyrate)
CategoryPharmaceutical (Orphan Drug)
Description

Pharmaceutical product for urea cycle disorders (UCDs), available as 500 mg tablets and 94% granules, that helps reduce elevated ammonia levels in patients with these rare metabolic conditions. OrphanPacific's first commercial product in Japan.

3Normosang (ノーモサング, hemin)
CategoryPharmaceutical (Orphan Drug)
Description

Normosang I.V. Injection 250 mg (hemin) administered via intravenous infusion for the improvement of acute attack symptoms in patients with acute porphyria, a group of rare inherited metabolic disorders.

4Dantrium (ダントリウム, dantrolene sodium hydrate)
CategoryPharmaceutical (Orphan Drug)
Description

Dantrium is available as a 20 mg IV formulation and 25 mg capsules containing dantrolene sodium hydrate, used for the treatment of malignant hyperthermia (a life-threatening reaction to general anesthesia) and neuroleptic malignant syndrome.

5Diazoxide (ジアゾキシド) 25 mg capsules
CategoryPharmaceutical (Orphan Drug)
Description

A 25 mg diazoxide capsule formulation indicated for the treatment of hyperinsulinemic hypoglycemia, a rare condition of recurrent low blood sugar caused by excessive insulin secretion.

6Rasiles (ラジレス, aliskiren fumarate) 150 mg tablets
CategoryPharmaceutical
Description

A 150 mg aliskiren fumarate tablet for the treatment of hypertension, distributed by OrphanPacific in Japan.

7Rynspad / Rinsupad (リンスパッド, dried concentrated human α1-proteinase inhibitor)
CategoryPharmaceutical (Orphan Drug)
Description

A 1000 mg IV infusion formulation of dried concentrated human α1-proteinase inhibitor (α1-antitrypsin) for the treatment of severe α1-antitrypsin deficiency, a rare hereditary disorder causing early-onset emphysema and liver disease.

8Astomin (アストミン, dimemorfan phosphate)
CategoryPharmaceutical
Description

A non-narcotic antitussive medication containing dimemorfan phosphate, available as 10 mg tablets, 10% powder, and 0.25% syrup formulations for the suppression of cough.

9Rabipur (ラビピュール, inactivated tissue culture rabies vaccine)
CategoryPharmaceutical (Vaccine)
Description

An inactivated tissue culture rabies vaccine for intramuscular injection (2.5 I.U. or more per dose) used for rabies prevention and post-exposure prophylaxis against rabies onset.

10Somazon (ソマゾン, mecasermin)
CategoryPharmaceutical (Orphan Drug)
Description

A human somatomedin C (IGF-1, mecasermin) preparation for injection used for treating conditions related to growth hormone deficiency and severe primary insulin-like growth factor deficiency.

11Orladeo (オラデオカプセル150mg)
CategoryPharmaceutical (Orphan Drug)
Description

Orladeo 150 mg capsule (icatibant) approved in Japan for the treatment of acute attacks of hereditary angioedema (HAE), a rare genetic disorder causing recurrent severe swelling.

12Joenja (ジョエンジャ, leniolisib)
CategoryPharmaceutical (Orphan Drug)
Description

Joenja (leniolisib) is an oral targeted therapy approved for the treatment of activated PI3K delta syndrome (APDS), a rare primary immunodeficiency, in patients aged 4 years and older. Commercialized by OrphanPacific in Japan under license from Pharming Group N.V.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2017-08-02
Description

OrphanPacific entered into a business partnership agreement with LTL Pharma Co., Ltd. for MR activities and academic operations. OrphanPacific began providing product information for LTL Pharma products (Solar Salt, Nivazil, Logan) through its MR activities. The partnership ended at a later date.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Nippon Shinyaku Co., Ltd.
TypeDirect peer
Description

Japanese pharmaceutical company with a meaningful rare disease and specialty pharma franchise alongside its core urology business. Directly comparable as a mid-cap Japanese pharma with an active rare disease commercialization arm and Japan-centric distribution model.

TypeDirect peer
Description

Japanese specialty pharmaceutical company focused on rare diseases, biopharmaceuticals, and regenerative medicine products. Comparable as a Japan-headquartered, mid-sized pharma commercializing rare disease and specialty therapies with a similar sales model targeting physicians and hospitals.

TypeDirect peer
Description

Japanese specialty pharmaceutical company with a global rare disease focus (notably in hematology and oncology). Comparable as a Japan-rooted pharma specializing in orphan and specialty therapies with biologics-based products commercialized through specialty channels.

4Chugai Pharmaceutical Co., Ltd.
TypeBroad incumbent
Description

Major Japanese pharmaceutical company (Roche group) with significant rare disease and specialty product portfolio, particularly in oncology and hematology. Comparable as a large Japan-headquartered pharma operating in overlapping rare disease therapeutic areas with extensive commercialization infrastructure.

TypeBroad incumbent
Description

Japan-headquartered global pharmaceutical major with a substantial rare disease and specialty franchise (especially post-Shire acquisition). Comparable as the dominant Japan-based pharma player in rare diseases globally, representing both a benchmark and a key competitive presence in Japan.

TypeBroad incumbent
Description

Established Japanese specialty pharmaceutical company with focus areas in oncology and rare diseases, including orphan drug development. Comparable as a larger Japanese specialty pharma with rare disease capabilities, representing a potential incumbent competitor for orphan assets and physician relationships.

TypeBroad incumbent
Description

Global leader in rare disease pharmaceuticals, now part of AstraZeneca, with deep experience commercializing ultra-orphan therapies including complement-mediated and metabolic disorders. Comparable as a global rare disease benchmark and as a potential competitor/partner for Japan market entry on overlapping indications.

TypeDirect peer
Description

Global rare disease specialist with a portfolio of orphan drugs for ultra-rare genetic conditions. Comparable as a pure-play rare disease commercializer focused on diseases with very small patient populations, providing a useful benchmark for orphan-drug business model economics.

9Sumitomo Pharma Co., Ltd.
TypeBroad incumbent
Description

Japanese pharmaceutical company with rare disease and specialty therapeutic areas (including regenerative medicine and oncology). Comparable as a Japan-rooted specialty pharma operating in overlapping rare disease indications with broader portfolio scope.

10AnGes, Inc.
TypeDirect peer
Description

Japanese specialty biotech focused on genetic and rare disease therapeutics. Comparable as a Japan-headquartered, smaller-cap company commercializing specialty therapies and leveraging partnerships for in-licensing and development.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

OrphanPacific

Orphan Pharmaceuticals (Rare Disease Drugs)orphanpacific.com

OrphanPacific is a Tokyo-based specialty pharmaceutical company that develops and commercializes orphan drugs for rare diseases in Japan, operating as a joint venture between CMIC Holdings and Medipal Holdings with a portfolio of approximately ten specialty products.

What OrphanPacific does

OrphanPacific, Inc. (株式会社オーファンパシフィック) is a Tokyo-based specialty pharmaceutical company founded on May 1, 2012 as a joint venture between CMIC Holdings Co., Ltd. (51%) and Medipal Holdings Corporation (49%) with paid-in capital of 100 million yen. The company develops and commercializes orphan drugs for rare diseases in Japan, addressing an estimated gap where approximately half of orphan drugs approved in the US and EU remain unapproved in Japan. Its portfolio spans approximately ten products including Buphenyl and Ravicti for urea cycle disorders, Normosang for acute porphyria, Dantrium for malignant hyperthermia and neuroleptic malignant syndrome, Diazoxide for hyperinsulinemic hypoglycemia, Rasilez for hypertension, Rynspad for severe α1-antitrypsin deficiency, Rabipur for rabies prevention, and the recently approved Joenja (leniolisib) for activated PI3K delta syndrome (APDS) and Ravicti oral liquid.

The company operates under its proprietary "Innovative Pharma Model" (IPM), which leverages CMIC Holdings' pharmaceutical development and manufacturing infrastructure alongside Medipal Holdings' pharmaceutical distribution network—one of Japan's largest—to efficiently bring globally-developed orphan drugs to Japanese patients. OrphanPacific generates revenue through pharmaceutical product sales (one-time licensing model) to healthcare institutions via a direct sales force of medical representatives (MRs), targeting physicians and pharmacists who treat rare disease patients. The company engages in licensing partnerships with international developers such as Pharming Group (Joenja) and Immedica Pharma (Ravicti) to expand its portfolio, distributes products through Medipal's wholesaler network, and supports healthcare professional and patient community engagement via medical conferences, disease awareness websites, and the OPOS online information service. Headcount stands at 51–100 employees, and the company recently relocated its Tokyo head office in July 2025.

OrphanPacific firmographics

Firmographics
Name
OrphanPacific
Legal name
OrphanPacific, Inc.
Website
https://orphanpacific.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
11–50 employees
Short description
OrphanPacific is a Tokyo-based specialty pharmaceutical company that develops and commercializes orphan drugs for rare diseases in Japan, operating as a joint venture between CMIC Holdings and Medipal Holdings with a portfolio of approximately ten specialty products.
Ownership category
akta.pro rank

OrphanPacific industry classification

Industry
Product category
Orphan Pharmaceuticals (Rare Disease Drugs)
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAL
Rare Gastroenterology & Hepatology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAG
Pulmonary Hypertension & Rare Pulmonary Disease Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAJ
Rare Endocrine & Growth Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Orphan drug development
  • Rare disease therapeutics
  • Specialty pharmaceuticals
  • Pharmaceutical distribution
  • Rare disease commercialization

Where OrphanPacific is headquartered

Location

Headquarters

HQ city
Tokyo
HQ country
Japan
HQ region
Asia

Offices1 record

Markets served

OrphanPacific business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain, Others

Revenue model

  1. Pharmaceutical product sales: OrphanPacific develops and commercializes orphan drugs (稀少疾病用医薬品) for the Japanese market, generating revenue through sales of specialty pharmaceuticals targeting rare diseases. Products include treatments for urea cycle disorders (Ravicti®, Buphenyl®), acute porphyria (Normosang®), malignant hyperthermia/malignant syndrome (Dantrium®), hyperinsulinemic hypoglycemia (Diazoxide), hypertension (Rasilez®), and alpha-1 antitrypsin deficiency (Rinsoeed™).

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

OrphanPacific product offering

Product offering

Core offering

OrphanPacific develops, in-licenses, and commercializes orphan drugs (rare disease pharmaceuticals) for the Japanese market under its proprietary Innovative Pharma Model (IPM). The company handles the full life cycle from obtaining marketing/manufacturing-sales approval to nationwide sales through medical representatives and pharmaceutical wholesalers, addressing rare conditions such as urea cycle disorders, acute porphyria, malignant hyperthermia, alpha-1 antitrypsin deficiency, hyperinsulinemic hypoglycemia, hypertension, and activated PI3K delta syndrome (APDS).

Product overview

OrphanPacific operates as a pharmaceutical company specializing in orphan drugs (稀少疾病用医薬品) for rare diseases in Japan. Their portfolio is not a unified software platform but rather a collection of prescription pharmaceutical products commercialized through licensing agreements. The company focuses on urea cycle disorders, acute porphyria, malignant hyperthermia, α1-antitrypsin deficiency, and other rare conditions. Products include Ravicti and Buphenyl for urea cycle disorders, Normosang for acute porphyria, Dantrium for malignant hyperthermia, and various other specialty pharmaceuticals.

Differentiator

Problem solved

Functional benefit

Products and services

  • Ravicti (ラヴィクティ, glycerol phenylbutyrate) Oral liquid formulation (1.1 g/mL) for the chronic management of urea cycle disorders (UCDs) — a group of rare inherited metabolic conditions in which the body cannot properly remove ammonia from the blood. Commercialized in Japan by OrphanPacific under license from Immedica Pharma AB; intended for patients with UCDs.
  • Buphenyl (ブフェニル, sodium phenylbutyrate) Pharmaceutical product for urea cycle disorders (UCDs), available as 500 mg tablets and 94% granules, that helps reduce elevated ammonia levels in patients with these rare metabolic conditions. OrphanPacific's first commercial product in Japan.
  • Normosang (ノーモサング, hemin) Normosang I.V. Injection 250 mg (hemin) administered via intravenous infusion for the improvement of acute attack symptoms in patients with acute porphyria, a group of rare inherited metabolic disorders.
  • Dantrium (ダントリウム, dantrolene sodium hydrate) Dantrium is available as a 20 mg IV formulation and 25 mg capsules containing dantrolene sodium hydrate, used for the treatment of malignant hyperthermia (a life-threatening reaction to general anesthesia) and neuroleptic malignant syndrome.
  • Diazoxide (ジアゾキシド) 25 mg capsules A 25 mg diazoxide capsule formulation indicated for the treatment of hyperinsulinemic hypoglycemia, a rare condition of recurrent low blood sugar caused by excessive insulin secretion.
  • Rasiles (ラジレス, aliskiren fumarate) 150 mg tablets A 150 mg aliskiren fumarate tablet for the treatment of hypertension, distributed by OrphanPacific in Japan.
  • Rynspad / Rinsupad (リンスパッド, dried concentrated human α1-proteinase inhibitor) A 1000 mg IV infusion formulation of dried concentrated human α1-proteinase inhibitor (α1-antitrypsin) for the treatment of severe α1-antitrypsin deficiency, a rare hereditary disorder causing early-onset emphysema and liver disease.
  • Astomin (アストミン, dimemorfan phosphate) A non-narcotic antitussive medication containing dimemorfan phosphate, available as 10 mg tablets, 10% powder, and 0.25% syrup formulations for the suppression of cough.
  • Rabipur (ラビピュール, inactivated tissue culture rabies vaccine) An inactivated tissue culture rabies vaccine for intramuscular injection (2.5 I.U. or more per dose) used for rabies prevention and post-exposure prophylaxis against rabies onset.
  • Somazon (ソマゾン, mecasermin) A human somatomedin C (IGF-1, mecasermin) preparation for injection used for treating conditions related to growth hormone deficiency and severe primary insulin-like growth factor deficiency.
  • Orladeo (オラデオカプセル150mg) Orladeo 150 mg capsule (icatibant) approved in Japan for the treatment of acute attacks of hereditary angioedema (HAE), a rare genetic disorder causing recurrent severe swelling.
  • Joenja (ジョエンジャ, leniolisib) Joenja (leniolisib) is an oral targeted therapy approved for the treatment of activated PI3K delta syndrome (APDS), a rare primary immunodeficiency, in patients aged 4 years and older. Commercialized by OrphanPacific in Japan under license from Pharming Group N.V.

Quantifiable outcome

  • Over 10 years of continuous orphan drug supply in Japan

Companies that use OrphanPacific

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

OrphanPacific technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

OrphanPacific partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • LTL Pharma Co., Ltd.minorStrategic or Co-development Partner · 2 August 2017OrphanPacific entered into a business partnership agreement with LTL Pharma Co., Ltd. for MR activities and academic operations. OrphanPacific began providing product information for LTL Pharma products (Solar Salt, Nivazil, Logan) through its MR activities. The partnership ended at a later date.

Scale indicators3 records

Recent moves7 records

Expansion highlights6 records

OrphanPacific competitors and assessment

Company assessment

Direct peers

  • Nippon Shinyaku Co., Ltd. Japanese pharmaceutical company with a meaningful rare disease and specialty pharma franchise alongside its core urology business. Directly comparable as a mid-cap Japanese pharma with an active rare disease commercialization arm and Japan-centric distribution model.
  • JCR Pharmaceuticals Co., Ltd. Japanese specialty pharmaceutical company focused on rare diseases, biopharmaceuticals, and regenerative medicine products. Comparable as a Japan-headquartered, mid-sized pharma commercializing rare disease and specialty therapies with a similar sales model targeting physicians and hospitals.
  • Kyowa Kirin Co., Ltd. Japanese specialty pharmaceutical company with a global rare disease focus (notably in hematology and oncology). Comparable as a Japan-rooted pharma specializing in orphan and specialty therapies with biologics-based products commercialized through specialty channels.
  • BioMarin Pharmaceutical Inc. Global rare disease specialist with a portfolio of orphan drugs for ultra-rare genetic conditions. Comparable as a pure-play rare disease commercializer focused on diseases with very small patient populations, providing a useful benchmark for orphan-drug business model economics.
  • AnGes, Inc. Japanese specialty biotech focused on genetic and rare disease therapeutics. Comparable as a Japan-headquartered, smaller-cap company commercializing specialty therapies and leveraging partnerships for in-licensing and development.

Broad incumbents

  • Chugai Pharmaceutical Co., Ltd. Major Japanese pharmaceutical company (Roche group) with significant rare disease and specialty product portfolio, particularly in oncology and hematology. Comparable as a large Japan-headquartered pharma operating in overlapping rare disease therapeutic areas with extensive commercialization infrastructure.
  • Takeda Pharmaceutical Company Limited: Japan-headquartered global pharmaceutical major with a substantial rare disease and specialty franchise (especially post-Shire acquisition). Comparable as the dominant Japan-based pharma player in rare diseases globally, representing both a benchmark and a key competitive presence in Japan.
  • Taiho Pharmaceutical Co., Ltd. Established Japanese specialty pharmaceutical company with focus areas in oncology and rare diseases, including orphan drug development. Comparable as a larger Japanese specialty pharma with rare disease capabilities, representing a potential incumbent competitor for orphan assets and physician relationships.
  • Alexion (AstraZeneca Rare Disease): Global leader in rare disease pharmaceuticals, now part of AstraZeneca, with deep experience commercializing ultra-orphan therapies including complement-mediated and metabolic disorders. Comparable as a global rare disease benchmark and as a potential competitor/partner for Japan market entry on overlapping indications.
  • Sumitomo Pharma Co., Ltd. Japanese pharmaceutical company with rare disease and specialty therapeutic areas (including regenerative medicine and oncology). Comparable as a Japan-rooted specialty pharma operating in overlapping rare disease indications with broader portfolio scope.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

OrphanPacific social profiles

Digital presence

OrphanPacific financial estimates

Financial estimate

Revenue estimate

Valuation estimate

OrphanPacific leadership team

Management profile

Number of profiles

Profiles1 record

OrphanPacific funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

OrphanPacific M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OrphanPacific

What does OrphanPacific do?

OrphanPacific develops, in-licenses, and commercializes orphan drugs (rare disease pharmaceuticals) for the Japanese market under its proprietary Innovative Pharma Model (IPM). The company handles the full life cycle from obtaining marketing/manufacturing-sales approval to nationwide sales through medical representatives and pharmaceutical wholesalers, addressing rare conditions such as urea cycle disorders, acute porphyria, malignant hyperthermia, alpha-1 antitrypsin deficiency, hyperinsulinemic hypoglycemia, hypertension, and activated PI3K delta syndrome (APDS).

Is OrphanPacific a public or private company?

OrphanPacific is a private company. It is classified as corporate owned and is currently operating.

When was OrphanPacific founded?

OrphanPacific was founded in 2012. It employs 11 to 50 people.

Where is OrphanPacific based?

OrphanPacific is headquartered in Tokyo, Japan, in the Asia region.

How does OrphanPacific make money?

One revenue line is on record: pharmaceutical product sales.

Who are OrphanPacific's main competitors?

Direct peers on record are Nippon Shinyaku Co., Ltd., JCR Pharmaceuticals Co., Ltd., Kyowa Kirin Co., Ltd., BioMarin Pharmaceutical Inc. and AnGes, Inc.. Broad incumbents are Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Taiho Pharmaceutical Co., Ltd., Alexion (AstraZeneca Rare Disease) and Sumitomo Pharma Co., Ltd..

Does OrphanPacific have an API?

No public API is recorded for OrphanPacific.

What industry is OrphanPacific in?

OrphanPacific's product category is Orphan Pharmaceuticals (Rare Disease Drugs). Its primary akta.pro industry code is HLAIAIAN, Rare Pediatric & Congenital Disorder Therapies, with a secondary code of HLAIAIAL, Rare Gastroenterology & Hepatology Disorder Therapies. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PrtimesNotice of obtaining domestic manufacturing and sales approval for the hereditary angioedema (HAE) attack suppression drug "Oradeo® granule package".Orphan Pacific obtained manufacturing and marketing approval in Japan for Oradeo granules, an oral plasma kallikrein inhibitor for hereditary angioedema in children aged 2 to under 12 weighing 15 kg or more. The four formulations (72mg, 96mg, 108mg, 132mg) provide once-daily suppression of acute attacks. Launch is planned after drug price listing procedures.PrtimesNotice of obtaining approval for partial change of manufacturing and sales approval for sodium phenylbutyrate for "Progressive Familial Intrahepatic Cholestasis (PFIC) Type 1 and Type 2"Orphan Pacific obtained approval from Japan's Ministry of Health, Labour and Welfare to add PFIC type 1 and 2 as indications for sodium phenylbutyrate (Buphenyl). The drug, developed with universities, was previously for urea cycle disorders but showed bile-secretion effects. The approval provides new treatment options beyond symptomatic therapy and liver transplantation.Stock TitanPharming Launches Joenja in Japan for APDS PatientsPharming Group announced the commercial launch of Joenja (leniolisib) in Japan for patients aged 4 and older with activated PI3K delta syndrome, following its inclusion on the Japan National Health Insurance drug price list. OrphanPacific, Inc. serves as the Marketing Authorization holder and is responsible for the product's supply and distribution in the region. This launch marks the first commercial availability of Joenja for children aged 4 to 11 worldwide.FinancialContent Business PagePharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and olderPharming Group announced the commercial launch of Joenja (leniolisib) in Japan for treating activated PI3K delta syndrome (APDS) in patients aged 4 and older, following its inclusion on the National Health Insurance drug price list. OrphanPacific, Inc. serves as the Marketing Authorization holder and is responsible for the product's supply and distribution in the region.PrtimesNotice of inclusion of the treatment drug for Activated PI3Kδ Syndrome (APDS) "Joenja® Tablets" (Generic name: Lenolisib) in the drug price standard.Orphan Pacific announced that leniolisib tablets for Activated PI3Kδ Syndrome (APDS) were added to Japan's drug price standard on August 13, 2026. The drug, approved March 23, 2026, targets adults and children over four, with prices ranging from 27,077.90 to 133,176.50 yen per tablet.PrtimesAnnouncement of the new release of the urea cycle disorder treatment drug "Ravicti® Oral Solution 1.1 g/mL"Orphan Pacific announced that Ravikiti oral solution, a phenylbutyric acid glycerol formulation for urea cycle disorder, is listed in Japan's drug price standard and available for sale. The sodium-free liquid allows smaller volumes and is expected to improve blood ammonia control and reduce treatment burden for patients.openPR.comPI3K Inhibitor Drug Class Market (2026-2033) | PI3Kα, PI3Kβ, PI3Kγ, Monotherapy & United States Growth | Top Companies 2026 - Novartis, iOnctura, OrphanPacific, TG Therapeutics, Inc., Verastem, Inc.DataM Intelligence published a market research report on the global PI3K Inhibitor Drug Class Market, valued at US$1.53 billion in 2025 and projected to reach US$2.3 billion by 2033 at a 5.5% CAGR. Key recent developments include Novartis agreeing in March 2026 to acquire the next-generation PI3Kα inhibitor SNV4818 from Synnovation Therapeutics for $2 billion upfront plus up to $1 billion in milestones, and Pharming Group receiving approval in Japan for Joenja (leniolisib), the first targeted therapy for activated PI3K delta syndrome in the country.Stock TitanPharming wins Japan approval for Joenja in APDSPharming Group N.V. announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Joenja (leniolisib) for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS) in patients aged 4 years and older. Joenja becomes the first approved treatment specifically for APDS in Japan and the first approved treatment globally for children aged 4 to 11 with the disease. OrphanPacific serves as the Marketing Authorization Holder for Joenja in Japan, with the product launch expected following agreement on National Health Insurance drug pricing.